Dr. John Cush RheumNow
7 years ago
REcent trial results from the Dermatology Meeting EADV in Madrid —shows rituximab superior to mycophenolate in Pemphigus Vulgaris; RTX 40% vs MMF 9.5% attained complete remission of pemphigus vulgaris, without steroids for > 16 weeks https://t.co/PU9CbQSHJV
Dr. John Cush RheumNow
7 years ago
Single center study of anti-PhosphoLipd Abs in 149 Bx proven lupus nephritis pts 36% had APL Abs (18.8% IgG, 18.1% IgM, 10.7% B2GlyP, 8.1% LAC). F/U of 156 mos - APL+ had lower 10 yr survival (91 vs 99%). lower GFR, more thrombotic events & miscarriage https://t.co/U5ra02wMmX
Among patients with systemic rheumatic diseases, the highest incidence of opportunistic infections was seen in those with polymyositis/dermatomyositis (PM/DM), Taiwanese researchers found.
Dr. John Cush RheumNow
7 years ago
SURVEY: When choosing drug therapy for GCA, what mechanism are you targeting? IL-1, IL-6, TNF, inflammation? Survey for RHEUMATOLOGISTS - please vote here>> https://t.co/qhpOxYz3Qt
Dannish study has shown that one-third of psoriatic arthritis (PsA) will have joint surgery that that PsA patients have twice the rate of joint surgery when compared with the general population.
The Danish National Patient Registry was used in this cohort study of incident PsA patients and their future risk of joint surgery compared to a general population cohort (GPC) between 1995-2012).
Dr. John Cush RheumNow
7 years ago
Statin induced myopathy is occurs in less than 1%; rhabdomyolysis and necrotizing myositis are very rare. HMGCR Abs against (HMG-CoA) reductase are seen 2- 3 of every 100,000 patients treated with statins. https://t.co/44DGaHEGjo
A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.
Dr. John Cush RheumNow
7 years ago
RheumNow Survey for Rheumatologists – In Giant Cell Arteritis - When do you add a steroid sparing agent? https://t.co/qhpOxYhsYV
Dr. John Cush RheumNow
7 years ago
RISE registry: among 7,274 RA pts w/ serial data [RAPID3 (78.9%) & CDAI (34.2%)]. Amongst those w/ moderate/high disease activity, frequency of DMARD change was low (36%-55%). Less likely to change was elderly, Combo DMARDs or biologics. https://t.co/IppHCxJWk1
Dr. John Cush RheumNow
7 years ago
Followup of 783 tofacitinib‐treated psoriatic arthritis patients finds increases in LDL and HDL 9% to 14% after 3 and 6 months of therapy with a low risk of HTN or MACE events https://t.co/fh6UbmF3lr
Dr. John Cush RheumNow
7 years ago
RheumNow LIVE VOTE Survey: When treating a patient for GCA, when might you add a steroid-sparing agent?? If youre a RHEUMATOLOGIST - please vote in our quick 4Q survey https://t.co/qhpOxYhsYV
A prospective analysis of newly diagnosed, inflammatory arthritis (IA) patients suggests that perceived distress (stress) increases the odds of incident IA.
Dr. John Cush RheumNow
7 years ago
Comparison of 69 SLE pts w/ C/S+ infection vs 69 SLE without infx shows that serum procalitonin did not distinguish those w/ infection, BUT C-reactive protein did successfully identify those SLE patients with infection https://t.co/HMHqfaP0Cg
A study of 527 patients receiving daily hydroxychloroquine (HCQ) concluded that hydroxychloroquine blood levels may predict future HCQ retinopathy.This study assessed whether lower HCQ dosing, as recommended by the 2016 American Academy of Ophthalmology (AAO) guidelines (less than 5 mg/kg), would favorably affect retinopathy outcomes.
Dr. John Cush RheumNow
7 years ago
Taiwanese Claims data study shows the risk of opportunistic infection in ~77K autoimmune pts shows OI highes in PM/DM cases (61.3/1000PY), followed by SLE (43.1/1000PY), SSc (31.6), RA (25), and pSS (24.1). OI risk highest during 1st year https://t.co/YKP7ZF7FIx

